Search

Displaying results 3101 - 3110 of 8469 in total
  1. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (β<sup>A-T87Q</sup>-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding capacity as … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  2. Drug

    Thiohexam

    go.drugbank.com/drugs/DB14200
    Approved

    Thiohexam is a rubber cure accelerator. It is also a known allergen and dermatological sensitizer. Sensitivity to Thiohexam may be identified with a clinical patch test.

  3. Drug

    Phenol

    go.drugbank.com/drugs/DB03255
    ApprovedInvestigational

    Phenol has been used to disinfect skin and to relieve itching. Phenol is also used as an oral analgesic or anesthetic in products such as Chloraseptic to treat pharyngitis. … During the second world war, phenol injections were used as a means of execution by the Nazis. Phenol is a toxic compound whose vapours are corrosive to the skin, eyes, and respiratory tract.

  4. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable

  5. Drug

    Ephedra sinica root

    go.drugbank.com/drugs/DB01363
    ApprovedNutraceutical

    The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for

  6. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    such as gastrointestinal behavior, atopic dermatitis, psoriasis, skin inflammation, and COVID-19. … EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions

  7. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  8. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  9. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including

  10. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Antitumor activity was not demonstrated and further development of BMS-753493 has been discontinued. … Epofolate has been used in trials studying the treatment of Advanced Solid Tumors.